News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
320,164 Results
Type
Article (20578)
Company Profile (209)
Press Release (299377)
Section
Business (101371)
Career Advice (1420)
Deals (16033)
Drug Delivery (42)
Drug Development (56270)
Employer Resources (102)
FDA (7195)
Job Trends (7278)
News (177497)
Policy (13384)
Tag
Academia (1366)
Africa (391)
Alabama (24)
Allergies (33)
Alliances (25263)
Alzheimer's disease (777)
Antibody-drug conjugate (ADC) (33)
Approvals (7169)
Arizona (51)
Artificial intelligence (36)
Asia (20777)
Australia (3545)
Bankruptcy (120)
Best Places to Work (5844)
Biosimilars (25)
C2C Services and Suppliers (18361)
California (582)
Canada (382)
Cancer (117)
Career advice (1187)
CAR-T (27)
Cell therapy (59)
China (31)
Clinical research (43483)
Collaboration (43)
Colorado (21)
COVID-19 (1389)
Cystic fibrosis (58)
Diagnostics (1982)
Diversity, equity & inclusion (25)
Drug pricing (29)
Earnings (38066)
Employer resources (88)
Europe (45677)
Events (53164)
Executive appointments (20)
FDA (7223)
Florida (58)
Funding (35)
Gene therapy (47)
GLP-1 (314)
Government (1854)
Healthcare (9046)
Hotbed/Location (224869)
Idaho (25)
Illinois (68)
Indiana (45)
Infectious disease (1394)
Inflammatory bowel disease (78)
Interviews (248)
IPO (8621)
Job creations (1476)
Job search strategy (1018)
Kansas (52)
Layoffs (232)
Legal (1975)
Liver cancer (26)
Lung cancer (21)
Management (30)
Manufacturing (24)
Maryland (151)
Massachusetts (318)
Medical device (4472)
Medtech (4472)
Mergers & acquisitions (7320)
Metabolic disorders (108)
Neuroscience (839)
New Jersey (41)
New York (54)
NextGen Class of 2024 (3175)
Non-profit (1880)
North Carolina (83)
Obesity (70)
Opinion (143)
Parkinson's disease (24)
Peanut (30)
Pennsylvania (27)
People (29970)
Phase I (14791)
Phase II (19779)
Phase III (13466)
Podcasts (20)
Policy (24)
Postmarket research (1193)
Preclinical (6067)
Rare diseases (74)
Real estate (2387)
Recruiting (43)
Regulatory (9961)
Research institute (1301)
Resumes & cover letters (237)
Series A (19)
South America (465)
Sponsored (20)
Startups (2758)
Texas (34)
United States (1781)
Vaccines (183)
Washington State (81)
Weight loss (65)
Date
Today (45)
Last 7 days (325)
Last 30 days (1256)
Last 365 days (25352)
2024 (14396)
2023 (26095)
2022 (31435)
2021 (33061)
2020 (29485)
2019 (22834)
2018 (16768)
2017 (17451)
2016 (15774)
2015 (18526)
2014 (13423)
2013 (9871)
2012 (10117)
2011 (10269)
2010 (9372)
320,164 Results for "star therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)
Star Therapeutics today announced the presentation of clinical data from VIVID 1 (VGA039 Investigation in Von Willebrand Disease), a Phase 1 clinical study of VGA039 in healthy volunteers.
June 26, 2024
·
4 min read
Drug Development
Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial
Starton Therapeutics Inc. announced today positive interim top-line data from its low-dose lenalidomide STAR-LLD Phase 1b clinical trial in multiple myeloma (MM).
June 21, 2024
·
4 min read
Drug Development
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients.
March 25, 2024
·
12 min read
Drug Development
Starton Therapeutics Announces Enrollment Completion for STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma
Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today the successful completion of enrollment for its STAR-LLD Phase 1b clinical trial in multiple myeloma.
April 25, 2024
·
4 min read
Drug Development
Verismo Therapeutics Announces Opening of Second Clinical Site for STAR-101 Phase 1 Trial
Verismo Therapeutics, a clinical-stage CAR-T company developing the novel KIR-CAR platform technology, today announced that it has activated a second clinical site for its STAR-101 Phase 1 clinical trial at The University of Texas MD Anderson Cancer Center.
March 7, 2024
·
2 min read
Business
Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer
Star Therapeutics today announced the appointment of Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer.
January 3, 2024
·
2 min read
Business
Star Therapeutics Appoints Matthew Fust as Independent Director and Board Audit Chair
Star Therapeutics today announced the appointment of Matthew Fust, a veteran finance executive in the life sciences industry, to its Board of Directors.
December 5, 2023
·
2 min read
Biotech Bay
Star Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Star Therapeutics today announced that Adam Rosenthal, Ph.D., CEO and Founder, will present a company overview at the 42nd annual J.P. Morgan Healthcare Conference on Thursday, January 11th at 10:30 a.m. PT.
January 2, 2024
·
1 min read
Pharm Country
Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma
Starton Therapeutics Inc. announced initial key safety and efficacy signals of its STAR-LLD Phase 1b clinical trial in multiple myeloma.
January 3, 2024
·
4 min read
Drug Development
Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update
Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced Regional Medical Oncology Center (RMOC) in Wilson, NC as the second site activated in the STAR-LLD Phase 1b clinical trial.
February 14, 2024
·
4 min read
1 of 32,017
Next
